Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

55.58USD
6 Dec 2016
Change (% chg)

$0.03 (+0.05%)
Prev Close
$55.55
Open
$55.71
Day's High
$55.95
Day's Low
$55.56
Volume
1,682,212
Avg. Vol
13,892,433
52-wk High
$77.12
52-wk Low
$49.03

Latest Key Developments (Source: Significant Developments)

Bristol-Myers receives positive CHMP opinion for Opdivo
Friday, 14 Oct 2016 06:59am EDT 

Bristol-Myers Squibb Co : Receives positive CHMP opinion for Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with Brentuximab Vedot . Says CHMP decision based on overall response rate demonstrated by data from two trials, Checkmate -205 and Checkmate -039 .CHMP recommendation will now be reviewed by European commission.  Full Article

U.S. FDA warns about the risk of Hepatitis B
Tuesday, 4 Oct 2016 05:31pm EDT 

: U.S. FDA warns about the risk of Hepatitis B reactivating in some patients treated with direct-acting antivirals for Hepatitis C .Requiring a boxed warning about risk of HBV reactivation to be added to drug labels of direct-acting antiviral medicines for Hepatitis C virus.  Full Article

Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration
Tuesday, 27 Sep 2016 06:59am EDT 

Bristol-myers Squibb Co : Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214 . Says Bristol-Myers Squibb and Nektar will equally share costs of combined therapy trials . Myers Squibb co - an initial dose-escalation trial is underway with Opdivo and NKTR-214 . Nektar will maintain its global commercial rights to NKTR-214 .Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214.  Full Article

Tianda Pharmaceuticals says Bristol-Myers Squibb to reacquire drug rights from unit<0455.HK>
Wednesday, 17 Aug 2016 05:12am EDT 

Tianda Pharmaceuticals Ltd <0455.HK>: Voluntary announcement-business update on investment in an oncology therapies research and development company <0455.HK> . Unit,ASLAN, announced Bristol-Myers Squibb would reacquire the rights to aslan002 in China, Australia, Korea, Taiwan and other Asian territories . Aslan will receive upfront payment of US$10 million and is eligible to receive development and regulatory milestones in excess of US$50 million . Aslan is eligible to receive royalty payments on future worldwide sales of its products .  Full Article

Aveo initiates evaluation of Tivozanib in combination with Bristol-Myers Squibb's opdivo in advanced renal cell carcinoma
Monday, 15 Aug 2016 07:00am EDT 

Aveo : Initiates Evaluation Of Tivozanib In Combination With Bristol Myers Squibb's Opdivo® (nivolumab) in advanced renal cell carcinoma .Phase 1/2 tinivo trial to commence at institut gustave roussy in paris.  Full Article

Moody's says Bristol-Myers Squibb's lung cancer trial result a major setback
Friday, 5 Aug 2016 02:01pm EDT 

Moody's on Bristol-Myers Squibb: Moody's: Bristol's lung cancer trial result a major setback .There is no impact on Bristol-Myers Squibb's A2/PRIME-1 ratings or stable rating outlook.  Full Article

Bristol-Myers' Opdivo fails late-stage study in patients with lung cancer
Friday, 5 Aug 2016 08:20am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb announces top-line results from checkmate -026, a phase 3 study of Opdivo (nivolumab) in treatment-naïve patients with advanced non-small cell lung cancer . Bristol-Myers Squibb announces top-line results from checkmate -026, a phase 3 study of opdivo (nivolumab) in treatment-naïve patients with advanced non-small cell lung cancer . Myers Squibb co - Opdivo did not meet trial primary endpoint of progression-free survival in patients expressing pd-l1 ≥ 5% .Myers Squibb co - will complete a full evaluation of checkmate -026 data and work with investigators on future presentation of results.  Full Article

Bristol-Myers Says in May sold business comprising an alliance with Reckitt Benckiser
Thursday, 28 Jul 2016 11:45am EDT 

: Bristol Myers Squibb - In May 2016, co sold the business comprising an alliance with Reckitt Benckiser Group including several OTC products sold primarily in Mexico and Brazil .Bristol Myers Squibb - Reckitt exercised its option to acquire the business, including a manufacturing facility, for $317 million, resulting in a gain of $277 million.  Full Article

Bristol-Myers squibb reports Q2 non-gaap EPS $0.69
Thursday, 28 Jul 2016 06:59am EDT 

Bristol-Myers Squibb Co : Myers Squibb reports second quarter financial results . Qtrly Opdivo worldwide revenues $840 million versus $122 million last year . Qtrly Sprycel worldwide revenues $451 million versus $405 million last year . FY2016 earnings per share view $2.60 -- Thomson Reuters I/B/E/S . Q2 revenue $4.9 billion versus I/B/E/S view $4.65 billion . Q2 earnings per share view $0.67 -- Thomson Reuters I/B/E/S . Sees FY 2016 non-gaap earnings per share $2.55 to $2.65 .Sees FY 2016 gaap earnings per share $2.43 to $2.53.  Full Article

Bristol-Myers Squibb collaborates with Johnson and Johnson for lung cancer research
Tuesday, 26 Jul 2016 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers squibb announces new research collaboration with janssen in immuno-oncology focused on lung cancer .Myers squibb co - phase 2 clinical trial will evaluate tolerability and clinical activity of combination of these agents in nsclc patients.  Full Article

BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment

* European Commission approves Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin